ConductScience.org, home

Paper41007745

Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.

Xenos D and 3 others. Biomedicines, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy. Papers, record 41007745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007745

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-03-07
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xenos DDimitrios
2Sotirchos VSVlasios Shttps://orcid.org/0000-0001-7278-1369
3Dimopoulos PMPlaton Mhttps://orcid.org/0009-0008-0565-5408
4Sofocleous CTConstantinos Thttps://orcid.org/0000-0002-3142-1399

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed

Source NIH RePORTER

Download CSV of grants

References205

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121514841CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.J Vasc Interv Radiol2011https://conductscience.org/library/papers/21514841PubMed
225351506Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.Eur J Nucl Med Mol Imaging2015https://conductscience.org/library/papers/25351506PubMed
311843249Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.Ann Oncol2001https://conductscience.org/library/papers/11843249PubMed
439745670Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90 Y Radiation Segmentectomy of Colorectal Liver Metastases.Clin Nucl Med2025https://conductscience.org/library/papers/39745670PubMed
512044059Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit.Neoplasma2002https://conductscience.org/library/papers/12044059PubMed
634342018A novel use of biomechanical model-based deformable image registration (DIR) for assessing colorectal liver metastases ablation outcomes.Med Phys2021https://conductscience.org/library/papers/34342018PubMed
725086245Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.Med Sci Monit2014https://conductscience.org/library/papers/25086245PubMed
833767862Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation.Mol Clin Oncol2021https://conductscience.org/library/papers/33767862PubMed
920567019
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
J Clin Oncol2010https://conductscience.org/library/papers/20567019PubMed
1033741643Dose-Response and Dose-Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer.J Nucl Med2021https://conductscience.org/library/papers/33741643PubMed
1134199556Thermal Ablation Compared to Partial Hepatectomy for Recurrent Colorectal Liver Metastases: An Amsterdam Colorectal Liver Met Registry (AmCORE) Based Study.Cancers (Basel)2021https://conductscience.org/library/papers/34199556PubMed
1239848272Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial.Lancet Oncol2025https://conductscience.org/library/papers/39848272PubMed
1339604694Radiation Lobectomy in Adjunct to Double Vein Embolization to Reach Sufficient Future Liver Remnant in Patients with Colorectal Cancer Liver Metastases: A Case Series.Cardiovasc Intervent Radiol2025https://conductscience.org/library/papers/39604694PubMed
1429755770Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases​.J Gastrointest Oncol2018https://conductscience.org/library/papers/29755770PubMed
1524906565Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy.Eur J Nucl Med Mol Imaging2014https://conductscience.org/library/papers/24906565PubMed
1627384594Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.AJR Am J Roentgenol2016https://conductscience.org/library/papers/27384594PubMed
1739225612The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors.Radiology2024https://conductscience.org/library/papers/39225612PubMed
1810861420Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.Cancer2000https://conductscience.org/library/papers/10861420PubMed
1923670568Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population.Cardiovasc Intervent Radiol2014https://conductscience.org/library/papers/23670568PubMed
2022199334Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.Anticancer Res2011https://conductscience.org/library/papers/22199334PubMed

See all 205 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42794898Histotripsy Outcomes for Primary and Metastatic Hepatic Disease.Cancers (Basel)2026https://conductscience.org/library/papers/42794898PubMed
42724862A SEER based SHAP interpretable prognostic nomogram for overall survival in surgically treated patients with colorectal cancer and synchronous liver metastasis.Transl Cancer Res2026https://conductscience.org/library/papers/42724862PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007745

GET https://conductscience.org/api/papers/v1/41007745/references?page=2